ABAFUNGIN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H22N4OS
Molecular Weight	378.491
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(C)=C(OC2=C(C=CC=C2)C3=CSC(N=C4NCCCN4)=N3)C=C1

InChI

InChIKey=TYBHXIFFPVFXQW-UHFFFAOYSA-N

InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)

HIDE SMILES / InChI

Molecular Formula	C21H22N4OS
Molecular Weight	378.491
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18587237 | https://web.archive.org/web/20070927102715/http://www.yorkpharma.com/media/YRK-Update_Abasol_061002-FN.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18587237 | https://www.google.com/patents/EP2331086A2

Abafungin is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses and onychomycosis. Abafungin acts through inhibition of transmethylation at the C-24 position of the sterol side chain, catalyzed by the enzyme sterol-C-24-methyltransferase. Abasol is a topical cream formulation of abafungin seeking approval in 2008 in European markets.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
sterol 24-C-methyltransferase activity 1 Target ID: GO:0003838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18587237	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatomycosis 20 Sources: https://www.google.com/patents/WO2009053741A2 https://www.google.com/patents/US20110059985 https://www.ncbi.nlm.nih.gov/pubmed/18587237	Primary		Phase III 665	Unknown Approved Use Unknown
Onychomycosis 18 Sources: https://www.google.com/patents/WO2009053741A2 https://www.google.com/patents/US20110059985 https://www.ncbi.nlm.nih.gov/pubmed/18587237	Primary		Phase III 665	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2010-04-13	20383346
Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.	2008	18587237

Patents

Sample Use Guides

In Vivo Use Guide

In formulated creams and gels, abafungin 1% to 30%, applied once daily for 1 to 3 months

Route of Administration: Topical

In Vitro Use Guide

MICs were determined using Kimmig’s and T3 media for dermatophytes, and YNB glucose and T3 medium for yeast-like fungi in physiological saline or in demineralized water. MIC's between 0.06 ug/mL and 1.0 ug/mL depending on species. The non-growing dermatophytes and yeastlike fungi were killed with Abafungin concentrations

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:40 GMT 2025`
Record UNII	11DI31LWXF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BAY W 6341

Preferred Name

English

ABAFUNGIN

Official Name

English

BAY-W-6341

Code

English

abafungin [INN]

Common Name

English

HEXAHYDRO-2-((4-(O-(2,4-XYLYLOXY)PHENYL)-2-THIAZOLYL)IMINO)PYRIMIDINE

Common Name

English

BAY-W-6341-

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C514